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Comparison of alpha–theta neurofeedback versus sensorimotor rhythm 
neurofeedback in the treatment of patients with fibromyalgia:  
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Abstract 
BACKGROUND: Fibromyalgia (FM) is a chronic disease with widespread musculoskeletal pain. In this study, we 
used neurofeedback to reduce pain and enhance the quality of life (QOL). 
METHODS: We conducted a double-blind randomized controlled trial (RCT) in 40 patients referred to Tuba Specialized 
Clinic and Clinic of Imam Khomeini Hospital in Sari, Iran, between December 2013 and July 2015. Group 1 
underwent sensorimotor rhythm (SMR) neurofeedback training and group 2 underwent neurofeedback training for 
alpha-theta training. The primary outcomes were pain reduction and increasing QOL, which were measured using 
Visual Analog Scale (VAS), Numeric Pain Scale, Fibromyalgia Impact Questionnaire (FIQ), and Medical Outcomes Study 
(MOS) Sleep Scale, respectively, within the first day, 4 weeks, and 8 weeks post-randomization. 
RESULTS: A total of 46 patients were screened for eligibility and 40 patients completed the trial. In both groups, 
the differences between FIQ scores before and after the study were statistically significant (P < 0.05). 
CONCLUSION: Neurofeedback training could be applied to reduce pain and improve the QOL of patients with FM. 
KEYWORDS: Neurofeedback; Fibromyalgia; Pain 
 
Date of submission: 04 July 2019, Date of acceptance: 13 Sep. 2019 
 
Citation: Farnia S, Kiani-Chelmardi M, Mobini M, Mehrpour A, Fattahi S, Zarghami M, et al. Comparison of 
alpha–theta neurofeedback versus sensorimotor rhythm neurofeedback in the treatment of patients with 
fibromyalgia: A randomized, double-blind, controlled clinical trial. Chron Dis J 2020; 8(3): 105-11. 
 
Introduction1 
Fibromyalgia (FM) is one of the most common 
musculoskeletal syndromes in adults. It also 
encompasses symptoms such as fatigue and 
sleep disturbances, morning stiffness, 
paresthesia, headache, and mood and 
cognitive disorders.1 The exact cause of the 
disease is unknown; however, some evidence 
indicates that FM is a non-inflammatory 
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syndrome.1,2 Onset of symptoms may be 
followed by a viral infection, psychological or 
physical damages, or may be slow and gradual 
with no clear cause.1,2 Several factors have been 
reported to be responsible for the pathogenesis 
of this syndrome including autonomic nervous 
system (ANS) disorders, peripheral decrease in 
cortisol response to stress, increased levels of 
neurotransmitters in cerebrospinal fluid (CSF), 
low levels of growth hormone (GH), low levels 
of metabolites of serotonin in CSF, and sleep 
disturbances.2 FM, after osteoarthritis (OA), is 
the most common diagnosis in rheumatology 






http://cdjournal.muk.ac.ir,    05 July 
Neurofeedback for fibromyalgia Farnia et al. 
  106   Chron Dis J, Vol. 8, No. 3, Summer 2020 
7 percent and in various studies, the 
prevalence rate among women and men has 
been reported 0.7% to 13.0% and 0.2% to 3.9%, 
respectively.2 FM is a multifaceted and 
complicated syndrome with relatively 
unpredictable process. Since the tolerance and 
response to treatment methods differs among 
patients, hence, choosing the most appropriate 
treatment for both the physician and the 
patient is difficult.3 The main goals of 
treatment are reducing pain and improving 
sleep in patients.1 Neurofeedback is one of the 
new methods introduced in the treatment of 
these patients, which is in fact operant 
conditioning of electrical activity of the brain.4,5 
Over the past decade, neurofeedback has 
been used to treat a wide range of psychiatric 
disorders. One of the neurofeedback protocols 
is “sensorimotor rhythm (SMR) reinforcement” 
that its effectiveness in reducing the symptoms 
of FM has been reported.6-8 Another protocols 
is "alpha-theta reinforcement" that is used to 
increase optimal and innovative performance, 
reinforce working memory, improve sleep 
quality, and treat anxiety disorders including 
generalized anxiety disorder (GAD),  
post-traumatic stress disorder (PTSD), anxiety 
and depression associated with alcohol use 
disorders, and insomnia.9-12 However, based 
on the available resources, this protocol has 
not been used in the treatment of FM so far. 
New criteria mainly emphasize on the 
clinical symptoms of widespread pain (diffuse) 
and neuropsychological symptoms.13 Patients, 
in addition to widespread pain, also complain 
about fatigue, stiffness, sleep disturbance 
[difficulty falling asleep, difficulty maintaining 
sleep, restless legs syndrome (RLS), and 
impaired breathing during sleep]. Analysis of 
genetic predisposing factors indicates the 
presence of neuropsychological routes shared 
with mood disorders and the role of the central 
mediators.14 Feeling of pain in patients with 
FM is affected by emotional and cognitive 
aspects that provide a solid foundation for the 
use of cognitive, therapeutic, and behavioral 
strategies.15,16  
Materials and Methods 
In two referral centers, Tuba Specialized Clinic 
and Imam Khomeini Hospital in Sari, Iran, we 
randomized patients in a double-blind, 
randomized controlled trial (RCT) comparing 
the clinical consequences of alpha–theta 
reinforcement neurofeedback therapy versus 
SMR reinforcement neurofeedback therapy 
between December 2013 and July 2015. All of 
the patients were under treatment with 50 to 
150 mg of pregabalin per day. Participants 
gave written informed consent at screening 
and were not paid for participating. 
The study was approved by the Ethics 
Committee of Mazandaran University of 
Medical Sciences, Sari (Reference Number: 
IR.MAZUMS.REC.94-907). This trial was 
registered at the Iranian Registry of Clinical 
Trials (IRCT) (code: IRCT2015022111885N4). 
We assessed the eligibility of all women 
with FM who referred to each of the two 
referral centers and were 18-50 years old. FM 
was diagnosed by a rheumatologist and based 
on American College of Rheumatology 
preliminary diagnostic criteria.1 The exclusion 
criteria were being younger than 18 years and 
older than 50 years, the presence of infectious 
diseases, chronic diseases such as cancer, 
diabetes, history of cardiovascular disease 
(CVD), rheumatologic diseases [such as lupus, 
rheumatoid arthritis (RA), etc.], history of neck 
and spine surgery, psychological disorders 
[including psychotic disorders, major 
depressive disorder (MDD), bipolar disorder, 
substance abuse disorders], use of psychiatric 
drugs (antidepressants, anti-anxiety, hypnotic, 
etc.), the incidence of unbearable side effects 
caused by intervention during the study, or 
unwillingness to participate in the study. 
A total of 46 patients were screened for 
eligibility and were randomized between 
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Figure 1. Participation consort flow diagram 
 
Two patients declined to participate in 
study and four patients refused to continue the 
trial. The ineffectiveness of treatment on the 
symptoms of illness and lack of adequate time 
for follow-up were mentioned as the reason for 
treatment refusal. Forty randomized patients 
completed the trial. 
At the beginning of the study, all eligible 
patients were assessed using Visual Analog 
Scale (VAS), Multiple Outcomes Study (MOS) 
Sleep Scale, and Fibromyalgia Impact 
Questionnaire (FIQ). The validity and reliability 
of FIQ have been approved by other studies.17 
The Persian translation of this questionnaire is a 
valid and reliable tool for assessing the health 
status of Persian-speaking patients with FM.18 
The validity and reliability of MOS Sleep Scale 
have also been demonstrated in previous 
studies.19-21 
MOS Sleep Scale measures 12 items in 6 
dimensions of sleep including sleep disorder, 
sleep efficiency, amount of sleep, sleepiness, 
snoring, and shortness of breath or headache. 
The sessions were twice a week (each for  
30 minutes) for a period of 4 weeks. Group  
1 underwent SMR neurofeedback training or 
training on Cz sensorimotor area and group  
2 underwent neurofeedback training for  
alpha-theta training on Pz area. 
Neurofeedback was performed using 
ProComp 2 devices and Thought Technology 
software in the neurofeedback unit of Imam 
Khomeini Hospital. 
In total, 40 patients were selected and 
randomly assigned to two groups (block 
randomization). First, a number was allocated 
to each patient, then they were assigned into 
blocks of 4 patients, and finally the blocks  
were studied using RANDBETWEEN function 
of Microsoft Excel software. Study 
investigators, research coordinators, attending 
care teams, and the patients were blinded to 
Assessed for eligibility (n = 46) 
Randomized (n = 44) 
Excluded (n = 2) 
Not meeting inclusion criteria (n = 0) 
Declining to participate (n = 2) 
Other reasons (n = 0) 
Allocated to alpha-theta training (n = 22) 
Receiving allocated intervention (n = 22) 
Not receiving allocated intervention (n = 0) 
Allocated to sensorimotor rhythm (SMR) 
neurofeedback (n = 22) 
Receiving allocated intervention (n = 22) 
Not receiving allocated intervention (n = 0) 
Lost to follow-up (n = 0) 
Discontinued intervention (n = 2) 
Analysed (n = 20) 
Excluded from analysis (n = 0) 
Lost to follow-up (n = 0) 
Discontinued intervention (n = 2) 
Analysed (n = 20) 
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treatment allocation. 
The primary outcomes were pain and 
quality of life (QOL), which were measured 
using VAS, Numeric Pain Scale, FIQ, and MOS 
Sleep Scale, respectively, at the beginning of 
study and at the end of eight sessions of 
neurofeedback (after four weeks); and four 
weeks after the last session of neurofeedback 
training were filled by patients. We estimated 
that a total of 40 patients would be needed to 
detect a difference between groups, with a 
two-tailed α of 0.05 and a  
(1-β) of 0.80, for a comparison of 2 
independent proportions. Repeated measures 
analysis of variance (ANOVA) was used to 
compare the results between the two groups. 
P-values of less than 0.050 were regarded as 
statistically significant. All analyses were 
conducted using SPSS software (version 16, 
SPSS Inc., Chicago, IL, USA). 
Results 
Baseline demographic and clinical 
characteristics were similar in both groups. 
The mean age of patients in group 1 (SMR 
neurofeedback training) was 41.64 ± 5.70 years 
and in group 2 (alpha-theta neurofeedback 
training) was 39.75 ± 5.06 years, that the 
difference was not statistically significant  
(P = 0.319). In both groups, there was 
statistically significant differences between the 
scores of VAS (pain severity) at the beginning 
of study, end of the fourth week, and end of 
the eighth week (P = 0.001). Nevertheless, 
using repeated measures ANOVA, there was 
not a statistically significant difference 
between the two groups (P > 0.050) (Figure 2). 
The FIQ: In group 1, there was a statistically 
significant difference in the mean scores of FIQ 
at the beginning (60.07 ± 12.08) and at the end 
of study (44.66 ± 14.09) (P < 0.001). In group 2, 
there was a statistically significant difference 
in the mean scores of FIQ at the beginning 
(56.77 ± 17.24) and at the end of study  
(38.30 ± 17.06) (P = 0.001). 
 
Figure 2. Visual Analog Scale (VAS) of pain 
during 8 sessions of neurofeedback treatment 
in alpha-theta and sensorimotor rhythm (SMR) 
neurofeedback groups 
 
The follow-up of patients showed a higher 
FIQ score after eighth week compared to the 
fourth week; nevertheless, the difference 
between initial and final (8 weeks) FIQ scores 




Figure 3. The Fibromyalgia Impact Questionnaire 
(FIQ) in alpha-theta and sensorimotor rhythm 
(SMR) neurofeedback groups 
 
MOS Sleep Scale: In group 1 patients, there was a 
statistically significant difference between MOS 
scores in the beginning and at the end of the 
study (P < 0.050). In group 2 patients, there was a 
statistically significant difference between MOS 
scores in the beginning and end of the forth 
week (P < 0.050). But the difference between the 
two methods was not statistically significant  
(P > 0.050). In this study, no statistically 
significant difference was observed between the 
two treatment protocols after the eighth week  
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Table 1. Mean and standard deviation (SD) of Medical Outcomes Study (MOS) Sleep Scale in both 
groups 
Neurofeedback protocol 1st day  
(mean ± SD) 
4th week  
(mean ± SD) 
8th week  










SMR 32.05 ± 6.45 34.78 ± 5.44 32.20 ± 5.01 0.042 0.370 
Alpha-theta 33.26 ± 4.02 35.68 ± 5.41 33.80 ± 4.30 0.045 0.040 
P (SMR/alpha-theta) 0.590 0.580 0.682 - - 




Neurofeedback facilitates inhibitory mechanisms 
in thalamus and can reconstruct the pain 
pathways in patients with FM.22 Some studies 
have also supported the hypothesis that 
neurofeedback can increase the amplitude of the 
delayed P300, that this triggers the inhibitory 
mechanism of the thalamus. The facilitation of 
inhibitory mechanisms may play a positive role 
in the central regulation of pain and changing 
the central reinforcement.23 This theory was the 
basis of this study for the use of neurofeedback 
in reducing pain in patients with FM. 
Few studies have been conducted to reduce 
pain by neurofeedback. These studies have 
shown that chronic pain is reduced by this 
method.24 For instance, the decrease in 
complex regional pain syndrome type I  
(CRPS-I) associated with migraine has been 
noted using neurofeedback method.16 
Furthermore, it has been shown that 
neurofeedback compared with escitalopram 
further improves the disease symptoms and 
QOL.6 All patients in our study during a  
4-week treatment with the two neurofeedback 
protocols, SMR and alpha-theta, sequentially 
mentioned lower pain intensity. As 
neurofeedback cannot affect the severity of 
symptoms immediately especially the pain, 
therefore, this led to the discouragement of 
patients to follow the treatment. The strength 
of our study compared to previous studies was 
the evaluation of two neurofeedback protocols 
at the same time and the comparison of the 
effectiveness of the two protocols including 
SMR reinforcement, which its effects on FM 
has been shown in previous studies and  
alpha-theta reinforcement protocol that its 
effect on patients with FM has not been 
investigated so far.25 Kayiran et al. conducted a 
randomized study but only the evaluator was 
blind to the intervention.6 None of the three 
other studies conducted in this context had 
randomized double-blind design with control 
groups.7,8,25 Similar to other studies, all 
participants in this study were women, which 
indicates very high prevalence of the disease 
among women.  
In the study by Kayiran et al.,6 patients who 
received neurofeedback and were not allowed 
to take any type of medication were compared 
with patients who received escitalopram. In 
the studies by Kravitz et al.5 and Nelson et 
al.,26 patients were allowed to take medications 
such as morphine, benzodiazepines, and 
serotonin reuptake inhibitors at the same time. 
But in our study, except taking pregabalin,  
the patients were not under treatment with 
any medication. 
The results of this study were consistent 
with the results of other studies. According to 
our results, both neurofeedback protocols were 
equally effective in reducing pain and this 
effect was maintained for up to 4 weeks after 
the treatment termination. In the study by 
Kayiran et al., patients were treated with 
neurofeedback for 4 weeks. VAS tool was used 
to measure the pain of patients. In this study, 
the patients’ pain was evaluated until week 24 
and according to the data, pain reduction 
process was clearly observed until week 8 and 
afterwards the treatment method showed no 
further beneficial effect in reducing pain.6 
In the present study, there was a statistically 
significant difference between FIQ scores of all 
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the end of the eight weeks of treatment. 
Similar to our results, in the study by Kayiran 
et al.6, which was conducted on a smaller 
number of patients in a shorter period of time, 
the FIQ scores significantly progressed during 
the study. 
 In another study by Nelson et al., 
conducted on 32 patients with FM, MOS Sleep 
Scale and FIQ were used to assess the effect of 
treatment on patients. In this study, patients 
were divided into two groups; one group was 
placebo feedback group and another group 
was treated actively with Low Energy 
Neurofeedback System (LENS) neurofeedback 
method. In this study, the amount of MOS 
significantly reduced during the study, which 
is in line with our results. Moreover, in this 
study, patients were followed up twice within 
3 months and 6 months after treatment.26  
On the other hand, Kravitz et al. conducted 
a study on 58 patients with FM. The FIQ 
questionnaires were completed by the patients 
before and after treatment. The results showed 
no statistically significant difference.5  
The results of the present study indicated 
that the use of alpha-theta neurofeedback, 
similar to SMR neurofeedback could be a 
suitable method in reducing pain in patients 
with FM and improving sleep quality and FIQ 
index in these patients. This result is consistent 
with the results of previous studies on the 
impact of relaxation techniques (relaxation) on 
decreasing pain.25 SMR neurofeedback training 
methods by strengthening amplitude of waves 
from 12 to 15 Hz can increase attention and 
concentration, cognitive processing, and sleep 
quality and can reduce fatigue.26 Unlike SMR 
training that is performed in the area of 
sensorimotor with open eyes, alpha-theta 
neurofeedback is performed with eyes closed 
and in a different location behind the head, and 
through 7 to 8 Hz reinforcement of the waves 
helps to induce relaxation and meditation and 
reduce stress and anxiety levels, and hence, 
demonstrates therapeutic effect.9,26  
Conclusion 
It can be said that performing any 
neurofeedback training protocol finally through 
instructing self-regulation can be effective in 
reducing the pain sensation and pain 
perception. Taken together, further studies with 
larger sample size and longer follow-up are 
recommended. In addition, the utilization of 
methods such as functional magnetic resonance 
imaging (fMRI) during the treatment is 
suggested to be able to more precisely examine 
the main mechanism of the disease and the 
effectiveness of treatment in patients. 
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